1.125
1.32%
-0.015
Rigel Pharmaceuticals stock is currently priced at $1.125, with a 24-hour trading volume of 6.45M.
It has seen a -1.32% decreased in the last 24 hours and a -20.77% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.14 pivot point. If it approaches the $1.12 support level, significant changes may occur.
Previous Close:
$1.14
Open:
$1.13
24h Volume:
6.45M
Market Cap:
$197.33M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-5.1136
EPS:
-0.22
Net Cash Flow:
$-20.74M
1W Performance:
+1.35%
1M Performance:
-20.77%
6M Performance:
+44.14%
1Y Performance:
-3.43%
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
1180 Veterans Boulevard, South San Francisco, CA
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-03-23 | Resumed | Piper Sandler | Neutral |
Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Mar-23-22 | Initiated | B. Riley Securities | Neutral |
Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
Sep-26-19 | Resumed | JP Morgan | Overweight |
Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
Aug-27-18 | Initiated | Citigroup | Buy |
May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
Dec-21-17 | Resumed | Piper Jaffray | Overweight |
Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
Nov-06-17 | Resumed | H.C. Wainwright | Buy |
Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
Jul-13-16 | Initiated | H.C. Wainwright | Buy |
Jun-13-16 | Initiated | Piper Jaffray | Overweight |
Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
Apr-08-13 | Reiterated | Stifel | Buy |
Nov-29-12 | Initiated | UBS | Neutral |
Nov-06-12 | Reiterated | Oppenheimer | Outperform |
Mar-26-12 | Initiated | Canaccord Genuity | Hold |
Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
Zacks Investment Research
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
Zacks Investment Research
OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
Zacks Investment Research
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
Zacks Investment Research
Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now
Zacks Investment Research
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Rigel Pharmaceuticals (RIGL) Revenue 2024
RIGL reported a revenue (TTM) of $116.88 million for the quarter ending December 31, 2023, a -2.79% decline year-over-year.
Rigel Pharmaceuticals (RIGL) Net Income 2024
RIGL net income (TTM) was -$25.09 million for the quarter ending December 31, 2023, a +57.16% increase year-over-year.
Rigel Pharmaceuticals (RIGL) Cash Flow 2024
RIGL recorded a free cash flow (TTM) of -$20.74 million for the quarter ending December 31, 2023, a +72.05% increase year-over-year.
Rigel Pharmaceuticals (RIGL) Earnings per Share 2024
RIGL earnings per share (TTM) was -$0.14 for the quarter ending December 31, 2023, a +58.82% growth year-over-year.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy. Rigel Pharmaceuticals, Inc. has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; BMS for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases. The company was incorporated in 1996 and is based in South San Francisco, California.
Cap:
|
Volume (24h):